SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects of cannabin...

Full description

Saved in:
Bibliographic Details
Published in:FEBS letters Vol. 350; no. 2; pp. 240 - 244
Main Authors: Rinaldi-Carmona, Murielle, Barth, Francis, Héaulme, Michel, Shire, David, Calandra, Bernard, Congy, Christian, Martinez, Serge, Maruani, Jeanne, Néliat, Gervais, Caput, Daniel, Ferrara, Pascual, Soubrié, Philippe, Brelière, Jean Claude, Le Fur, Gérard
Format: Journal Article
Language:English
Published: England Elsevier B.V 22-08-1994
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes. After intraperitoneal or oral administration SR141716A antagonises classical pharmacological and behavioural effects of cannabinoid receptor agonists. This compound should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0014-5793
1873-3468
DOI:10.1016/0014-5793(94)00773-X